Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
Cancer Treat Rev. 2013 Jun;39(4):388-401. doi: 10.1016/j.ctrv.2012.12.006. Epub 2013 Jan 12.
To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management.
We performed a PubMed and Cochrane-based review of side effects associated with the seven agents including product monographs to provide an outline of treatment measures aiming to reduce their toxicities. Subject and outcome of interest, design type, sample size, pertinence and quality, and detail of reporting were the indicators of manuscript quality.
All targeted therapies cause adverse events. Most adverse events may be prevented or tested before they escalate to severe levels.
Prevention, early recognition, and prompt management of side effects are of key importance and avoid unnecessary dose reductions, which may undermine treatment efficacy.
提供舒尼替尼、帕唑帕尼、贝伐珠单抗、替西罗莫司、阿昔替尼、依维莫司和索拉非尼相关不良事件及其管理的最新综述。
我们对包括产品专论在内的七种药物相关副作用进行了基于 PubMed 和 Cochrane 的综述，旨在提供旨在降低其毒性的治疗措施概述。感兴趣的主题和结果、设计类型、样本量、相关性和质量以及报告的详细信息是手稿质量的指标。
所有靶向治疗都会引起不良反应。大多数不良反应可以在其恶化到严重程度之前预防或检测。
预防、早期识别和及时处理副作用至关重要，可避免不必要的剂量减少，从而降低治疗效果。
